# Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic Malignancies

> **NCT05705505** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Traws Pharma, Inc.** · enrollment: 60 (estimated)

## Conditions studied

- Endometrioid Endometrial Cancer

## Interventions

- **DRUG:** Narazaciclib
- **DRUG:** Letrozole 2.5mg

## Key facts

- **NCT ID:** NCT05705505
- **Lead sponsor:** Traws Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-03-29
- **Primary completion:** 2026-01
- **Final completion:** 2026-02
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2023-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05705505

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05705505, "Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05705505. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*